ImmunityBio (IBRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of nine directors, each recommended by the board for approval.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.
Proxies may vote on other business that may properly come before the Annual Meeting at their discretion.
Board of directors and corporate governance
The slate of director nominees includes Patrick Soon-Shiong, Cheryl L. Cohen, Richard Adcock, Michael D. Blaszyk, Wesley Clark, Linda Maxwell, Christobel Selecky, Barry J. Simon, and Bruce Wendel.
Audit committee and external auditor matters
Deloitte & Touche LLP is recommended for ratification as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ImmunityBio
- Q1 2026 revenue surged 168% to $44.2M, but net loss deepened to $632.8M on non-cash charges.IBRX
Q1 20267 May 2026 - Record revenue growth, global approvals, and robust governance highlight this year's proxy.IBRX
Proxy filing30 Apr 2026 - 700% revenue growth to $113M, global expansion, and net loss narrowed to $351M.IBRX
Q4 202530 Apr 2026 - Global immunotherapy expansion accelerates with durable clinical results and new market launches.IBRX
The Citizens Life Sciences Conference 202628 Apr 2026 - ANKTIVA drives global immunotherapy growth with strong efficacy, approvals, and financial momentum.IBRX
Investor presentation11 Mar 2026 - FDA approval, robust NMIBC efficacy, and global expansion drive strong growth.IBRX
Investor Day 20253 Feb 2026 - Stockholders will vote on director elections, a new equity plan, and auditor ratification.IBRX
Proxy Filing1 Dec 2025 - Key votes include director elections, equity plan approval, and auditor ratification.IBRX
Proxy Filing1 Dec 2025 - Strong ANKTIVA uptake, global expansion, and pivotal trial progress drive near-term milestones.IBRX
Jefferies London Healthcare Conference 202519 Nov 2025